Bone Marrow Neoplasm

In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC)

PMID 21865346 · Cortes et al., 2011 · Open in CIViC

In an in vitro study, a Ba/F3 murine cell line stably expressing the H396R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to bosutinib treatment (IC50: 33.… (full text at CIViC)

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with H396R and E355G variants in 9/11 and 1/11 clones, respectively.… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

In a retrospective study of 174 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL1fusion positive accelerated phase chronic myeloid leukemia patients, patients with mutations in the AB… (full text at CIViC)

PMID 19487385 · Apperley et al., 2009 · Open in CIViC

In a retrospective study of 84 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL1 fusion positive (Ph+) chronic myeloid leukemia (in accelerated-phase or with blast crisis) or Ph+ acut… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing a H396R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (1.3 nmol/L vs. 0.8 nmol/L… (full text at CIViC)

PMID 15930265 · O'Hare et al., 2005 · Open in CIViC

In an in vitro study, a Ba/F3 cell line stably expressing the H396R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was found to have increased sensitivity to dasatinib treatment, as compa… (full text at CIViC)

PMID 15256671 · Shah et al., 2004 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An accelerated-phase patient had a return to chr… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL p… (full text at CIViC)

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations … (full text at CIViC)

PMID 15930265 · O'Hare et al., 2005 · Open in CIViC

In a study of 39 chronic phase CML patients with BCR-ABL variants, H396R was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. … (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

In an in vitro study, a Ba/F3 murine cell line stably expressing the L248V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to bosutinib treatment (I… (full text at CIViC)

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In this phase II multinational study, 60 imatinib-resistantpatients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. 44 (73%) of 60 BCR-ABL mutant patients achie… (full text at CIViC)

PMID 17264298 · Guilhot et al., 2007 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL p… (full text at CIViC)

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 3 had L248V mutations

PMID 17264298 · Guilhot et al., 2007 · Open in CIViC

In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The L248V mutation in th… (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

One chronic myeloid leukemia patient in chronic phase had no response to imatinib. Bacterial clones generated using peripheral blood RNA later showed the BCR-ABL1 fusion with the L364I secondary varia… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In an in vitro study, Ba/F3 cell line stably expressing the L384M mutation in the ABL1 portion of the BCR-ABL fusion protein was associated with reduced sensitivity to dasatinib treatment (IC50: 4.04 … (full text at CIViC)

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

One chronic myeloid leukemia patient in chronic phase with the BCR-ABL1 fusion and the F486S secondary variant in 2/11 clones had partial best cytogenetic response to imatinib before becoming complete… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The L384M mutation in th… (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

In a study of 39 chronic phase CML patients with BCR-ABL variants, L387F was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. … (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib. The L387F mutation in the ABL1 portion of the BCR-ABL1 fu… (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing a L387M mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (2.0 nmol/L vs. 0.8 nmol/… (full text at CIViC)

PMID 15930265 · O'Hare et al., 2005 · Open in CIViC